Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 p.m. ET. A live webcast will be available via the Investors section of Kiniksa's website, with a replay posted within approximately 48 hours.
Positive
- None.
Negative
- None.
News Market Reaction – KNSA
In the Feb 26 session, KNSA gained 1.71%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings results | Positive | -8.2% | Strong 2025 ARCALYST growth and profitability with 2026 revenue outlook. |
| Feb 19 | Earnings date notice | Neutral | +2.7% | Announcement of scheduled Q4 and full-year 2025 results call. |
| Jan 12 | Corporate update | Positive | -3.6% | Unaudited 2025 ARCALYST revenue, growth metrics, and pipeline milestones. |
| Jan 7 | Conference presentation | Neutral | -1.6% | J.P. Morgan Healthcare Conference appearance and webcast details. |
| Nov 12 | Conference presentation | Neutral | -0.7% | Jefferies Global Healthcare Conference presentation and webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows KNSA often trading lower after fundamentally positive updates and around conference appearances, indicating frequent negative price divergence from ostensibly constructive news.
Over the last few months, Kiniksa reported strong ARCALYST growth and a move to profitability, with Q4 2025 net product revenue of $202.1M and full-year 2025 revenue of $677.6M, yet shares fell 8.21% after earnings on Feb 24. January’s corporate update also coincided with a 3.63% decline. Multiple conference participation announcements on Jan 7 and Nov 12 saw modest negative reactions. Today’s TD Cowen conference news fits a pattern of generally neutral events occurring against a backdrop of selling pressure following strong fundamentals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
